首页 News 正文

Johnson&Johnson Opsynvi single tablet combination therapy approved by FDA

我放心你带套猛
217 0 0

Johnson&Johnson announced on the 23rd that the US FDA has approved its Opsynvi monotherapy combination therapy for long-term treatment of adult patients with pulmonary arterial hypertension (PAH) classified as II-III by the World Health Organization (WHO) Functional Classification (FC). The approval of Opsynvi enables Johnson&Johnson's PAH product portfolio to cover all PAH targeted pathways recommended by the guidelines. It is reported that Opsynvi is the first FDA approved PAH single tablet combination therapy. The approval of Opsynvi by the US FDA is mainly based on the results of key Phase 3 clinical studies of A DUE, in which Opsynvi demonstrates that patients have a greater reduction in pulmonary vascular resistance (PVR) after 16 weeks of treatment compared to monotherapy with tadalafil or macitabine.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

我放心你带套猛 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    31